OSTX (OS Therapies Incorporated) קצב צמיחת רווח למניה בשנה הנוכחית

Relying on grants for the development of targeted therapy for rare bone tumors, OS Therapies Incorporated (OSTX) maintains high volatility. The annual amplitude of EPS changes demonstrates instability in the course, while the 24.60 indicator expresses the state of the metric. A lack of sales and the burning of funds on R&D preclude a stable cash flow, and the expansion of clinical trials only increases current costs.

OS Therapies Incorporated (OSTX) focuses on developing osteosarcoma therapies, which makes its profit dependent on clinical trial results. By analyzing annual EPS fluctuations, an investor can see the net income per share dynamics compared to the same period last year. This metric is calculated as the percentage deviation of the current EPS value from the baseline. For this company, the indicator reflects the efficiency of its capital burn rate. A negative trend confirms the R&D stage and a lack of sustainable operational self-sufficiency.